These findings were extended to show that loss of RUNX1T1 also inhibits the viability of PAX3-FOXO1 fusion alveolar rhabdomyosarcoma (aRMS) and MYC-driven small cell lung cancer (SCLC) cells. Here, RUNX1T1 is linked to rhabdomyosarcoma.